Andrew David Fesnak, MD
Pathology and Laboratory Medicine
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Penn Medicine Provider

About me

  • Associate Professor of Clinical Pathology and Laboratory Medicine

Education and training

  • Medical School: University of Medicine and Dentistry of New Jersey
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Fesnak is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Wang Y, McKenna D, Spitzer T, Brunker P, Nedelcu E, Fesnak A, Celluzzi C, DiGuardo M, Jacob EK Training in cell and gene therapy manufacturing: Unmet needs and arguments for graduate medical education , Transfusion, 66(1): 2026,259-265


Verschraegen CF, Hashibe M, Neill US, Pirl W, Hexner EO, O'Connell A; NASDC Consortium NCI Awardee Skills Development Consortium (NASDC): a Successful Novel Educational Effort to Maintain Early Academic Competitiveness: PART 1-Overview of the NASDC Coordinating Center , J Cancer Educ: 2025


Petrella J, Dai A, Mackey S, Correa A, Brennan AL, Fesnak A, Siegel D, Plesa G Feasibility of Releasing Fresh CART Cell Products for Infusion Based On Studying Product Post-Harvest Stability , Cytotherapy, 27(5): 2025,2


Fesnak, A T Cell and Related Immunotherapies , Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: 2024


Fesnak, A Gene Therapy , Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: 2024


Mackey S, Dai A, Davis MM, Fesnak A, Siegel D, Plesa G Flow Cytometry Case Studies Illustrating Comprehensive Approach Required For Developing, Optimizing, And Implementing Multicolor Panels For The Manufacturing And Release Of Investigational Cell Therapy Products At UPenn , Cytotherapy, 26(6): 2024,S137-S138


Mack EA, Dougher MC, Ginda AM, Cahill C, Murter M, Schell K, Tanhehco YC, Bhoj VG, Fesnak AD, Siegel DL, Kambayashi T, Aqui NA, O'Doherty U Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis , Blood, 143(11): 2024,1049-1054


Wang K, Tseng CY, Li Z, White C, Wang B, Levine BL, Fesnak AD A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy , Cytotherapy, 25(12): 2023,1370-1379


Plesa G, Brennan AL, Levine JR, Hasenmayer D, Buchholz K, Migliaccio T, Holland D, Colligon TA, Mackey S, Dai A, Petrella J, Ngo S, Fesnak A, Davis MM, Siegel D Multiple Efficiencies Gained by Implementing a Significantly Shorter Manufacturing Schedule for Production of CAR T Cell Products , Cytotherapy, 25(6): 2023,S9


Mackey, S., Dai, A., Gong, N., McGettigan, B., Jefferson, P., Petrella, J., Gohil, M., Fesnak, A., Siegel, D., Davis, M. M., Plesa, G. Developing and Optimizing Multicolor Flow Cytometry Methods for the Manufacturing and Release of 3-Day HuCART Products , Cytotherapy, 25(6): 2023,S189-S190


View all publications